{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["208(1)"],"submitter":["Thiruvengadam SK"],"funding":["Genentech, Inc.","Genentech"],"pubmed_abstract":["A high unmet need for novel, safe and effective therapies exists among older patients with non-Hodgkin lymphoma (NHL). We report safety and efficacy of mosunetuzumab in a subgroup analysis of a phase I/II study, which examined the prognostic impact of age in 218 patients with relapsed/refractory (R/R) B-cell NHL (B-NHL; ≥65 years, n = 102; <65 years, n = 116) from the phase I expansion cohort (NCT02500407) and further evaluated 90 patients with R/R follicular lymphoma (FL; ≥65 years, n = 30; <65 years, n = 60) from the pivotal cohort. The most common adverse event (AE) was cytokine release syndrome, occurring less frequently in older versus younger (33.3% vs. 44.8%) patients with B-NHL. Serious AEs were similar in older versus younger patients (45.1% vs. 46.6%). For patients with R/R FL, o"],"journal":["British journal of haematology"],"pagination":["149-158"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12819098"],"repository":["biostudies-literature"],"pubmed_title":["Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study."],"pmcid":["PMC12819098"],"pubmed_authors":["Zhou M","Mei M","Wu M","Thiruvengadam SK","Yin S","Zuo X","Popplewell LL","Nikolaenko L","Mun Y","Budde LE","Herrera AF","Wei MC"],"additional_accession":[]},"is_claimable":false,"name":"Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study.","description":"A high unmet need for novel, safe and effective therapies exists among older patients with non-Hodgkin lymphoma (NHL). We report safety and efficacy of mosunetuzumab in a subgroup analysis of a phase I/II study, which examined the prognostic impact of age in 218 patients with relapsed/refractory (R/R) B-cell NHL (B-NHL; ≥65 years, n = 102; <65 years, n = 116) from the phase I expansion cohort (NCT02500407) and further evaluated 90 patients with R/R follicular lymphoma (FL; ≥65 years, n = 30; <65 years, n = 60) from the pivotal cohort. The most common adverse event (AE) was cytokine release syndrome, occurring less frequently in older versus younger (33.3% vs. 44.8%) patients with B-NHL. Serious AEs were similar in older versus younger patients (45.1% vs. 46.6%). For patients with R/R FL, o","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T19:29:44.765Z","creation":"2026-06-04T03:10:51.136Z"},"accession":"S-EPMC12819098","cross_references":{"pubmed":["41254806"],"doi":["10.1111/bjh.70212"]}}